Compare McKesson Corporation (MCK) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Wipro Limited — how do they compare? McKesson Corporation trades at $824.66 (market cap $97.35B), while Wipro Limited trades at $1.87 (market cap $18.49B). The key difference: McKesson Corporation is far larger — about 5.3× Wipro Limited's market cap, and Wipro Limited pays the higher dividend (4.68%). Which is the better fit depends on your goals.
| MCK | WIT | |
|---|---|---|
Market Cap | $97.35B | $18.49B |
Sector | Health | Technology |
52-Week High | $995.69 | $3.06 |
52-Week Low | $659.01 | $1.82 |
Enterprise Value | $101.98B | $16.42B |
Dividend Yield | 0.39% | 4.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
WIT trades at $1.855, down 0.27% with bearish technical signals. Recent quarters show earnings misses against expectations, though 2025 revenue was $890.88B with net income of $131.35B. Valuation ratios appear reasonable with P/E of 13.97 and P/B of 1.96. Analyst consensus is mixed with 19% buy ratings amid concerns about client spending and AI investments.
The outlook remains cautious due to earnings volatility and competitive pressures. Investment appeal hinges on AI partnership execution and margin stabilization, while risks include geopolitical uncertainty and tech spending constraints. Cash flow strength provides some buffer against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
